Abstract 4740
Background
Primary cerebral lymphoma (PCL) is a rare malignancy representing less than 1.5% of brain tumors. Given the lack of studies in the literature that describe PCL, we used data from the Surveillance, Epidemiology, and End Results (SEER) database to investigate PCL’s prognostic factors, incidence and survival rates.
Methods
We conducted a retrospective population-based cohort study using SEER database from 1983-2014. Patients with primary lymphoma as their only primary malignancy analyzed. Patients who were diagnosed by autopsy, had no active follow up in the registry and with unknown Ann Arbor Staging, or radiology status were excluded. We also calculated the frequencies and the average annual age-adjusted rate (AAR) of PCL patients between 2000 and 2015. Uni- and multivariable accelerated failure time regression were used to identify possible prognostic factors affecting the patient’s survival.
Results
We identified 1,196 PCL cases, with an average age of diagnosis 56.71 ± 17.28 years and 59.9% were males. Diffuse B-cell lymphoma was the most prevalent sub-type (61.3%). AAR was 0.14 per 100,000. These rates were higher in males, Asian or Pacific Islander and increasing with age. PCL-specific 1-year, 2-year, and 5-year survival rates were 89.6%, 84.4%, and 67%, respectively. Increased age (HR: 1.02, 95%CI=1.01–1.03, P < 0.001) and recent diagnosis after 2002 (HR: 2.42, CI = 1.46–3.42, P < 0.001) were significantly associated with shorter survival, while having a PCL in the temporal lobe (HR: 0.62, 95%CI=0.40–0.98, P = 0.040), or parietal lobe (HR: 0.63, 95%CI=0.42–0.94, P = 0.024) as compared to the other sites, and receiving radiation (HR: 0.37, 95% CI = 0.15–0.92, P = 0.033) or chemotherapy (HR: 0.64, 95%CI=0.50–0.83, P = 0.001) were associated with improved survival.
Conclusions
This is the first report to shed light on PCL’s incidence, survival rate, and prognostic factors. As a result, it will provide physicians and researchers with insights about this rare malignancy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sherief Ghozy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2182 - Evaluating the prevalence of the expression of PD-L1 in NSCLC specimens with short-duration formalin fixation using IHC 22C3 pharmDx
Presenter: Keiichi Ota
Session: Poster Display session 1
Resources:
Abstract
5255 - [18F]-FDG PET/CT in predicting PD-L1 status in nasopharyngeal carcinoma
Presenter: Liang Zhao
Session: Poster Display session 1
Resources:
Abstract
4910 - Expression of PD-L1 in Chinese Patients with Common Cancers
Presenter: Min Zheng
Session: Poster Display session 1
Resources:
Abstract
4227 - The clearance of EGF by tumor-associated macrophages is suppressed by chemotherapeutic agent cisplatin
Presenter: Irina Larionova
Session: Poster Display session 1
Resources:
Abstract
5222 - VHIO-300 and a thousand one nights, a tale of Precision Medicine
Presenter: Ginevra Caratù
Session: Poster Display session 1
Resources:
Abstract
5668 - Matched Whole-Genome Sequencing and Whole-Exome Sequencing with Circulating Tumor DNA (ctDNA) Analysis are complementary modalities in clinical practice
Presenter: Robin Imperial
Session: Poster Display session 1
Resources:
Abstract
5772 - Exploring the role of genes associated with familial cancer syndromes on the development of multiple primary tumors
Presenter: Atanaska Mitkova
Session: Poster Display session 1
Resources:
Abstract
4784 - Doxorubicin resistance: early and advanced tumors can use two different strategies based on initial and profound abnormalities in microRNA expression signature
Presenter: Volodymyr Halytskiy
Session: Poster Display session 1
Resources:
Abstract
3456 - From tumor transcriptomes to underlying cell type proportions to better predict prognosis and response to treatments
Presenter: Yuna Blum
Session: Poster Display session 1
Resources:
Abstract
4976 - Optimization of automated germline DNA extraction from non-tumoral formalin-fixed paraffin embedded (FFPE) tissues
Presenter: Omar Youssef
Session: Poster Display session 1
Resources:
Abstract